“This is a rare opportunity for me personally, this is my only hope to extend my life by any real period at all." The post ...

A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs.

A UCSF team discovers that a notorious cancer-causing enzyme called SRC exists on the outside of many tumors - so they're ...

Now, researchers at the University of California, San Francisco (UCSF), have discovered that Src also appears like a flag on the surface of bladder, colorectal, breast, pancreatic, and probably many ...

Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...

Zymeworks presents six posters at AACR highlighting advancements in antibody-drug conjugates and T cell engagers, including ZW209's promise in lung cancer. Zymeworks Inc. announced the presentation of ...

Score will leverage Asimov’s CHO Edge system to accelerate the development of enhanced cancer immunotherapies with improved ADCC activity ...

The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...

Antibody-drug conjugates (ADCs) link cancer drug payloads, such as tubulin inhibitors and DNA damaging agents, to monoclonal antibodies that selectively target tumor cells. Pernille Hemmingsen, PhD, ...

A new wave of immuno-therapies is reshaping the fight against cancer, turning the body’s own immune system into a powerful ...